TNF and rheumatoid arthritis: A phase III clinical trial in which ozoralizumab, a humanized trivalent bispecific Nanobody® molecule (now approved by Taisho as Nanozora®) consisting of two anti-TNF VHHs and one anti-human serum albumin VHH, was combined with methotrexate (MTX) in MTX-resistant rheumatoid arthritis patients showed a significant decrease in disease symptoms compared to patients receiving MTX alone (JapicCTI identifier: 184029).